2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.
Byoung Chul Cho, MD, PhD, a professor at the Yonsei Cancer Center and Severance Hospital, discusses the updated efficacy reported with repotrectinib (TPX-0005) in TKI-naïve patients with ROS1-positive non–small cell lung cancer (NSCLC).
The updated efficacy data from the phase 2 TRIDENT-1 study, as well as the pooled data from the phase 1/2 portion of the study, were presented during the 2020 World Conference on Lung Cancer, according to Cho.
Clinical activity was observed in patients who were TKI naïve with ROS1-positive NSCLC in the phase 1/2 portion of the trial. These patients had received at least 2 post-baseline scans, notes Cho. These patients achieved a high and promising response rate, says Cho. Moreover, patients from the phase 2 portion of the trial experienced a high confirmed objective response rate, Cho concludes.